English | Español
Patient Daily | Dec 1, 2025

PhRMA Senior Director on 340B abuse: 'If Congress is serious about lowering drug costs, they must reform 340B'
Patient Daily | Dec 1, 2025

Six companies continue work on cell therapy despite recent industry exits
Patient Daily | Dec 1, 2025

New hereditary angioedema treatments expand options but patient switching remains limited
Patient Daily | Dec 1, 2025

Health organizations urge annual flu shots amid high-severity season
Patient Daily | Dec 1, 2025

Early introduction linked with sharp drop in childhood peanut allergies
Patient Daily | Dec 1, 2025

International team launches effort to speed up advances in follicular lymphoma research
Patient Daily | Nov 30, 2025

Researchers call for expanded monitoring after finding global spread of hidden antibiotic-resistant genes
Patient Daily | Nov 30, 2025

Regional conflicts worsen global surge in cholera amid rising climate threats

Trending
+ Pharmaceuticals
Patient Daily | Apr 5, 2026

Amplifon announces $2 billion acquisition of GN Hearing in strategic shift
Patient Daily | Apr 7, 2026

ProPublica examines impact of RFK Jr.'s vaccine policies on childhood disease risks
+ Regulatory
Patient Daily | Apr 9, 2026

Reason Foundation commentator on vaccine liability: 'Exposing vaccine makers to the machinations of trial lawyers will stymie the development of innovative vaccines'
+ Regulatory
Patient Daily | Apr 8, 2026

Columbia University Professor Masia on 340B: '340B has become a drug mark-up program. Hospitals buy drugs at low cost and sell them high'